Our scientific team collaborates with you to define objectives, select optimal cell lines, and design screen-specific conditions such as treatment timing, MOI, and phenotype definition.
Traditional in vitro screening methods often fall short in capturing the complexity of cellular behavior, leading to data that lack translational value. Genome-scale in vivo screening, redefined at the mammalian cell level, preserves the natural state of cells and allows for precise functional interrogation of the entire genome. Recent landmark studies demonstrated increased screening sensitivity using empirically designed sgRNA libraries in human cell lines, while other groups identified stress-responsive and drug-resistance genes in live cell systems using pooled CRISPR screening. The strategy integrates the robustness of in vivo conditions with the scalability of high-throughput screening, delivering results that reflect true gene function within intact cells.
Are you grappling with inconsistent in vitro results, poor biological relevance, or limited gene function data in complex cell systems? Our genome-scale in vivo screening service at Creative Biolabs enables high-throughput discovery of critical gene functions in live mammalian cells, preserving native regulatory landscapes, cellular heterogeneity, and context-specific phenotypes. Powered by high-coverage CRISPR libraries, physiologically relevant cell models, and robust readout technologies, this platform brings you closer to real biological outcomes, without relying on animal models.
By capturing gene function in complex yet controllable systems, we bridge the gap between genomic exploration and therapeutic innovation.
Our service features next-generation sgRNA libraries targeting over 20,000 genes, optimized for mammalian cells. Each sgRNA is computationally and empirically validated for maximum efficiency and minimal off-target activity. We also offer focused libraries for specific pathways, such as DNA repair, immune modulation, apoptosis, or kinases.
We conduct screens directly in physiologically relevant mammalian cell types—including immortalized lines (e.g., A549, HeLa, HEK293), primary cells (e.g., T cells, macrophages), and iPSC-derived cell types. This ensures realistic gene expression patterns, proper epigenetic regulation, and intact cellular signaling networks.
Our platform enables screening under biologically meaningful conditions—chemical stress, cytokine stimulation, co-culture systems, hypoxia, or viral infection—mimicking disease-relevant microenvironments within a cellular framework. This allows for identification of condition-specific gene dependencies or resistance mechanisms.
Screens can be read out via fluorescence-based enrichment, cell viability assays, immunophenotyping, FACS sorting, or bulk/single-cell RNA-seq, depending on the experimental design. Our team tailors each readout method to maximize sensitivity and resolution.
Using state-of-the-art tools and machine-learning-based models, we provide deep insight into enriched or depleted sgRNAs, pathway-level effects, and synergistic gene interactions. Each report includes ranked gene lists, significance scores, and actionable follow-up suggestions.
Creative Biolabs offers a fully integrated, end-to-end genome-scale in vivo screening service at the cellular level, with customized modules and expert consultation throughout the process. We specialize in:
From initial experimental design to in-depth bioinformatic analysis, we ensure that your project progresses seamlessly and delivers robust, publication-quality results.
Our scientific team collaborates with you to define objectives, select optimal cell lines, and design screen-specific conditions such as treatment timing, MOI, and phenotype definition.
We prepare high-quality lentiviral or AAV-based sgRNA libraries tailored to human or mouse genomes, ensuring high coverage and minimal sequence bias.
Cells are transduced at low MOI (to ensure one sgRNA per cell), selected for successful integration, and expanded to maintain library representation across the population.
Cells are subjected to defined challenges (e.g., drug, cytokine, environmental change), with phenotypic selection occurring naturally or via sorting and gating strategies.
Genomic DNA is extracted and sgRNA abundance is profiled using next-generation sequencing. Library diversity and hit strength are assessed across biological replicates.
Results are analyzed using robust statistical frameworks and visualized through custom reports highlighting top hits, enriched pathways, and follow-up recommendations.
Our cell-level in vivo screens offer a powerful alternative to animal models, reducing ethical concerns while increasing biological relevance.
Screen whole genomes or target specific pathways, across a variety of mammalian cell types and conditions.
Process thousands of genes in a single experiment with rapid, reproducible, and statistically powerful outputs.
From vector design to data visualization, our experts ensure technical excellence and scientific rigor.
Experience the Creative Biolabs Advantage – Get a Quote Today
Genome-scale CRISPR screening at high sensitivity with an empirically designed sgRNA library shows that single-cell clones with stable Cas9 expression achieve significantly higher editing efficiency than bulk populations. Consistent and robust Cas9 levels in these clones lead to more reliable and sensitive knockout performance across targets, highlighting the importance of using optimized cell lines for high-precision CRISPR functional screening.
Fig.1 Single-cell Cas9 clones achieve markedly higher editing efficiency than mixed bulk populations.1
A: Yes. Our protocols are optimized for both high-throughput immortalized lines and sensitive primary or iPSC-derived cells with slower growth kinetics.
A: Absolutely. We offer activation (CRISPRa) and inhibition (CRISPRi) libraries for gene overexpression or transcriptional suppression studies in mammalian cells.
A: Our sgRNA libraries are designed with validated on-target efficiency scores and minimal predicted off-targets. We also offer hit validation using individual sgRNAs.
A: We offer arrayed screens, individual knockout lines, transcriptomic profiling, and functional assays to confirm screen hits.
Custom-engineered lines for pathway-specific or phenotypic reporters.
Individual sgRNA per well for high-content imaging or detailed phenotypic analysis.
Assess gene–gene interactions or synthetic lethality using combinatorial perturbation.
Merge CRISPR screen results with transcriptomic, proteomic, or metabolomic data for a systems biology perspective.
Creative Biolabs' genome-scale in vivo screening service provides an advanced, mammalian-cell-based solution for high-throughput gene function discovery. Whether you're mapping signaling pathways, identifying druggable targets, or decoding resistance mechanisms, our platform delivers robust, biologically relevant insights without animal models. Flexible, scalable, and data-rich, it's the new standard for functional genomics.
Contact Our Team for More Information and to Discuss Your Project – We're Ready to Help!
Reference